The pandemic has accelerated our progress in developing new methods to test taste and smell worldwide. Innovations include conducting supervised sensory testing via Zoom, using unsupervised computer surveys, or doing tests by mail, with postcards that can be self-administered online. A future vision would be a single standardized taste and smell test adopted as a clinical standard in medicine worldwide, similar to hearing and vision tests. The lack of a universal standing makes it hard to compare the results from the over 250 studies of people tested for taste and smell loss with COVID-19 because it is difficult to know if study-to-study differences are due to testing methods or other variables. As a step toward this vision, a recent mailout study of adults of different ancestry illustrates those bitterness intensity ratings collected via Zoom match expectations from their underlying genotype, a data quality control of the worldwide sensory data. New organizations like the Global Consortium of Chemosensory Research have advanced chemosensory testing by quickly translating tests into many languages, further supporting this vision. Challenges to this vision are numerous. They include the costs of stimuli, distributing them promptly and efficiently, the need to have odorants that are familiar to all people, maintaining sensory stimuli concentrations and storage in different environments, and ensuring that participants follow testing instructions. Surmounting these challenges is possible but will require cooperation among the many interested in developing and implementing these standards.